Monday’s Stock Winners: Eli Lilly (LLY), Nurix (NRIX), and Broadcom (AVGO) Rally

Key Highlights

• Technology stocks tied to artificial intelligence, including Broadcom, AMD, Nvidia, and Super Micro, recovered Monday following Friday’s market downturn
• Eli Lilly shares climbed as much as 5% following positive Phase 3 results for its obesity medication Foundayo across diverse menopause populations
• Nurix Therapeutics shares skyrocketed 38% on news of a $2.3 billion partnership with Roche, featuring a $700 million immediate payment
• Flex and Marvell Technology advanced after official confirmation of their S&P 500 index addition effective June 22
• Honeywell shares declined 2% despite maintaining annual projections and revealing restructuring plans following aerospace division separation

Monday morning trading showed signs of recovery from the artificial intelligence sector selloff that impacted Friday’s session. Technology equities advanced during premarket hours as investors shifted focus away from Middle East tensions involving Israel and Iran, as well as previous week’s sector anxieties.

Broadcom climbed 1.5% before the opening bell following two consecutive days of declines linked to disappointing revenue projections. AMD shares increased 1.6%, while Nvidia advanced 1.9%, and Super Micro Computer surged 7.7%. Additional semiconductor and storage companies including Micron Technology, Lam Research, Seagate, and Western Digital also positioned for positive openings.

Broadcom Inc., AVGO

Eli Lilly Rallies on Foundayo Clinical Results

Eli Lilly emerged as a top performer Monday, with shares advancing between 3.9% and 5%. The pharmaceutical company disclosed fresh clinical data from its ATTAIN-1 and ATTAIN-2 studies during the weekend.

The clinical trials demonstrated that Foundayo produced significant weight reduction outcomes in female participants across all menopause classifications. Within the ATTAIN-1 study, women receiving the maximum dosage experienced body weight reductions ranging from 12.8% to 14.4% throughout the 72-week treatment period.

Approximately 83% of study participants achieved a minimum 5% reduction in body weight. Nearly 52% of participants experienced weight loss exceeding 15%. These outcomes remained consistent across premenopausal, perimenopausal, and postmenopausal populations.

The clinical evidence strengthens the market opportunity for Lilly’s obesity treatment portfolio and may facilitate upcoming reimbursement negotiations with insurance companies and medical organizations.

Nurix Shares Explode on Major Roche Partnership

Nurix Therapeutics claimed the title of largest single-stock gainer Monday, with shares jumping 38% following announcement of a significant collaboration with Roche.

The worldwide exclusive licensing and development agreement encompasses the advancement and marketing of bexobrutideg, an oral BTK degrader compound. The arrangement carries a potential value reaching $2.3 billion.

Nurix will receive an immediate cash payment of $700 million. Roche agrees to fund 60% of development expenses, while Nurix assumes responsibility for the remaining 40%. Both organizations will split U.S. market profits and losses on an equal basis.

For international territories, Roche assumes full commercialization duties and compensates Nurix through tiered royalty payments ranging from low-to-high teen percentages. The agreement’s non-dilutive financing structure received positive reception from the investment community.

Both companies intend to initiate a Phase 3 clinical study this summer targeting chronic lymphocytic leukemia. Additional therapeutic applications under investigation include multiple sclerosis and chronic spontaneous urticaria.

S&P 500 Additions and Honeywell Developments

Marvell Technology and Flex both posted gains following official confirmation from S&P Dow Jones Indices regarding their S&P 500 inclusion scheduled for June 22. Marvell shares jumped 6.7% while Flex increased 3%.

Honeywell shares dropped 2% despite confirming its 2026 annual revenue outlook of $38.8 billion to $39.8 billion. The industrial conglomerate also presented an updated financial structure for its automation-centered business unit in preparation for the aerospace division spinoff planned for June 29.

Apple shares edged higher by 0.3% in anticipation of its 2026 Worldwide Developer Conference, which commenced Monday.

The post Monday’s Stock Winners: Eli Lilly (LLY), Nurix (NRIX), and Broadcom (AVGO) Rally appeared first on Blockonomi.